Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Excretion of [14C]BTZ-043 in Healthy Men
NCT04874948Phase 1Completed
- Start
- Oct 2021
- Primary completion
- Oct 2021
- Modality
- Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BTZ-043 in Tuberculosis (TB). Primary endpoints: Rates and Routes of Excretion, Pharmacokinetics of Total Radioactivity in Blood and Plasma (Cmax) and 6 more. Started Oct 2021; status: completed.
02
Drugs
BTZ-043
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04874948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04874948.